Listed by the USPTO as DEKARSKE, MADELINE MCGUIRE
Tech Center 1600 • Art Units: 1622 1634 1674 1675
This examiner grants 20% of resolved cases
DEKARSKE, MADELINE MCGUIRE is a USPTO patent examiner in tech center 1600 and art unit 1622. Only 5 resolved cases are reported, with an allowance rate of 20.0%. The median time to allowance is 1053 days, and interview lift is 50.0%. The limited case base makes the interview figure directional rather than a dependable prediction.
The principal companies are Dana-Farber Cancer Institute Inc., Genentech Inc., and BASF SE. The leading firms are COOLEY LLP, MARSHALL, GERSTEIN & BORUN LLP, and Acuity Law Group, P.C. Application-specific review should drive prosecution decisions, with interviews considered where direct discussion may clarify claim scope.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18557225 | CLASS IIA HISTONE DEACETYLASE (HDAC) DEGRADER LIGANDS AND METHODS OF USE THEREOF | Final Rejection | DANA-FARBER CANCER INSTITUTE, INC. |
| 18540310 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | Non-Final OA | Genentech, Inc. |
| 18684280 | PYRAZINE COMPOUNDS FOR THE CONTROL OF INVERTEBRATE PESTS | Non-Final OA | BASF SE |
| 18412362 | METHODS AND COMPOSITIONS FOR TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION | Non-Final OA | Northwestern University |
| 18359651 | SYNTHESIS OF COMPLEX 15N-LABELED MOLECULES | Non-Final OA | The Trustees of Columbia University in the City of New York |
| 18227122 | SETDB1-MICROTUBULE INTERACTION AND USE THEREOF | Non-Final OA | ARIEL SCIENTIFIC INNOVATIONS LTD. |
| 18550474 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | Final Rejection | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18550504 | INHIBITORS OF PLASMA KALLIKREIN | Non-Final OA | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18546300 | COMBINATION OF A SERCA2 INHIBITOR AND A STING ACTIVATOR FOR USE IN TREATING AND/OR PREVENTING CANCER | Non-Final OA | Université de Montpellier |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy20.0% of resolved applications examined by Madeline Mcguire Dekarske were allowed (5 resolved cases), compared with 60.6% across Art Unit 1622 over the last five years.
This examiner's interview lift is +50.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Madeline Mcguire Dekarske took 1,053 days on average from filing to allowance.
Madeline Mcguire Dekarske examines applications in Art Unit 1622 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
